The Lantern Vol. 73, No. 1, Fall 2005

• Newspaper Clippings Found on the Wall of Giuseppe Luchenzo\u27s Home When it was Raided by Police • All the Time in the World • The Man Who Would Win • Souffle Suit • A Day in the Mind • Context • Felicity / Awareness • Frivolous • Thank You Note to J.S.B. • September 17, 2005 • Eight Ways of Looking at a Highway • Dusty Glass Spreads Air Like Light • Clockwork • Rubber Band • Outside Eye or I Am? • A Mundane Mysticism • Half Carat • Things I Learned on My Trip to the Mutter Museum of Medical Oddities • Peer Editing • The Attic Bones • Yeshttps://digitalcommons.ursinus.edu/lantern/1167/thumbnail.jp

The Lantern Vol. 73, No. 2, Spring 2006

• Of the Man • Beauty in America • Kindling • Genevieve • Bits of Copper • A Love Song to Hip Hop • From James\u27 Journal • I Want a Woman • Peregrine Rain • Resurge • Frustrations • (At Least) You Gave Me Something to Write About • The Fun of Giving Interactive History Lectures as a Summer Job • Exigence • White Water • My Summer, with Salt • The City With Two Faces • I Dig Your Cello • Life-Filled Ghost Town • Laura, On Happiness • Integration/Assimilation • Sunny Side Estates • Every Night I Shut My Eyes • New England State of Mind • Your Body\u27s Weight in Water for Your Soul, Thank You Very Much • A Story That\u27s 10 Percent Truehttps://digitalcommons.ursinus.edu/lantern/1168/thumbnail.jp

Concordance between Clinical Practice and Published Evidence: Findings from The National Dental Practice-Based Research Network

Documenting the gap between what is occurring in clinical practice and what published research suggests is an important step toward improving care. This study quantified concordance between clinical practice and published evidence across preventive, diagnostic and treatment procedures among a sample of dentists in the National Dental Practice-Based Research Network

Individual effect of recrystallisation nucleation sites on texture weakening in a magnesium alloy: Part 1- double twins

Recrystallised grain nucleation, grain growth and corresponding texture evolution in a cold-rolled rare earth containing WE43 Mg alloy during annealing at 490 �C was fully tracked using a quasi-in-situ electron backscatter diffraction method. The results show nucleation sites, such as double twins, can weaken the deformed texture and for the first time provide direct evidence that recrystallised grains originating from double twins can form the rare earth texture during annealing. Precipitation and recrystallisation occurred concurrently during most of the annealing period, with precipitates forming preferentially along prior grain and twin boundaries. These precipitates effectively retard the recrystallisation due to particle pinning leading to an excessively long time for the completion of recrystallisation. A large portion of recrystallised grains were observed to have 〈0001〉 poles tilted 20e45� away from the normal direction. The RE texture emerges during the nucleation of recrystallised grains and is maintained during subsequent uniform grain growth, which results in a stable RE texture being developed as recrystallisation progresses. The uniform grain growth could be attributed to solute drag suppressing the grain boundary mobility of those grains that had recrystallised with a basal texture and precipitate pinning restricting potential orientated grain growth

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline